Trevi Therapeutics reports Q1 net loss of $6.4M; plans three chronic cough trials in H2 2023

Trevi Therapeutics, Inc.

2023-Q1 EPS reported -$0.06

Net loss of $6.4M in Q1 2023 vs. $7.3M in Q1 2022; cash and equivalents $111.3M.
Plans to initiate Phase 2b trial for chronic cough in IPF, Phase 1b respiratory physiology trial, and Phase 2a refractory chronic cough trial in H2 2023.
Received Notice of Allowance for U.S. patent covering oral nalbuphine ER for chronic cough in IPF, expected expiration 2039.
Completed open-label extension of Phase 2b/3 PRISM trial for prurigo nodularis; will request End of Phase 2 meeting with FDA.
Completed part 1 of human abuse potential study; selected butorphanol dose for part 2.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Trevi Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income a net loss of $6.4 million.

Period: the quarter ended March 31, 2023
Net income: a net loss of $6.4 million
Result: reported results

Exact text from the filing

For the first quarter of 2023, the Company reported a net loss of $6.4 million, compared to a net loss of $7.3 million in the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Trevi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021229

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.